Published in Pediatr Hematol Oncol on September 26, 1996
Human parvovirus B19. Clin Microbiol Rev (2002) 3.44
Human Parvoviruses. Clin Microbiol Rev (2017) 0.84
Human parvovirus, the cause of erythema infectiosum (fifth disease)? Lancet (1983) 4.41
Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). J Hyg (Lond) (1983) 4.13
Human parvovirus arthropathy. Lancet (1985) 3.76
An outbreak of erythema infectiosum associated with human parvovirus infection. J Hyg (Lond) (1984) 3.38
Acute parvovirus B19 infection associated with fulminant hepatitis of favourable prognosis in young children. Lancet (1998) 2.31
Electron microscopy of hepatitis B core antigen synthesized in E. coli. Nature (1982) 2.25
Human parvovirus infection in pregnancy and hydrops fetalis. N Engl J Med (1987) 2.23
Cost-effectiveness of a smoking cessation program after myocardial infarction. J Am Coll Cardiol (1993) 2.18
Immune response to B19 parvovirus and an antibody defect in persistent viral infection. J Clin Invest (1989) 2.08
Mitigation of experimental inflammatory bowel disease in guinea pigs by selective elimination of the aerobic gram-negative intestinal microflora. Gastroenterology (1974) 1.95
Immediate and long term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol (1998) 1.88
Postnatal persistence of spongy myocardium with embryonic blood supply. Arch Pathol (1975) 1.86
Impact of group psychological interventions on pregnancy rates in infertile women. Fertil Steril (2000) 1.85
Application of a screening test for antibody the hepatitis B core antigen. J Clin Pathol (1977) 1.85
5-Azacytidine, a new, highly effective cancerostatic. Experientia (1964) 1.84
Comparison of radioimmunoassay and counter-immunoelectrophoresis for the detection of antibody to hepatitis B core antigen. J Virol Methods (1981) 1.65
Acyclic nucleotide analogues: synthesis, antiviral activity and inhibitory effects on some cellular and virus-encoded enzymes in vitro. Antiviral Res (1990) 1.57
Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med (1989) 1.55
Human parvovirus and the fetus. Lancet (1985) 1.50
Human parvovirus infection in early rheumatoid and inflammatory arthritis. Ann Rheum Dis (1986) 1.47
Has oral fluid the potential to replace serum for the evaluation of population immunity levels? A study of measles, rubella and hepatitis B in rural Ethiopia. Bull World Health Organ (2001) 1.40
Revisiting carotid sinus denervation in carotid sinus hypersensitivity. Am Heart J (1994) 1.40
Ethylene glycol intoxication misdiagnosed as eclampsia. Acta Anaesthesiol Scand (2006) 1.39
The IgM antibody responses to the core antigen of hepatitis B virus. J Med Virol (1978) 1.39
Colonization patterns of aerobic gram-negative bacteria in the cloaca of Rana pipiens. Lab Anim Sci (1974) 1.38
A comparison of oral fluid collection devices for use in the surveillance of virus diseases in children. Public Health (2001) 1.37
Hepatitis C virus antibody. Lancet (1989) 1.33
Accurate serodiagnosis of B19 parvovirus infections by measurement of IgG avidity. J Infect Dis (1995) 1.31
Cytokinin-derived cyclin-dependent kinase inhibitors: synthesis and cdc2 inhibitory activity of olomoucine and related compounds. J Med Chem (1997) 1.28
Detection of parvovirus B19 in donated blood: a model system for screening by polymerase chain reaction. J Clin Microbiol (1993) 1.24
Haemagglutination by parvovirus B19. J Gen Virol (1992) 1.23
[24-hour monitoring of blood pressure in patients with essential hypertension]. Vnitr Lek (1993) 1.21
Structure and mapping of the DNA of human parvovirus B19. J Gen Virol (1987) 1.19
Dot blot hybridization assay of B19 virus DNA in clinical specimens. J Clin Microbiol (1989) 1.18
More cases of SIADH with fluoxetine. Am J Psychiatry (1990) 1.17
Cardiomyopathy accompaning industrial cobalt exposure. Br Heart J (1972) 1.17
Transmission of serum parvovirus-like virus by clotting-factor concentrates. Lancet (1983) 1.15
Incidence of sudden cardiac death, myocardial infarction and far- and near-transyears. Biomed Pharmacother (2005) 1.10
Early alterations of the cardiac muscle cells in isoproterenol-induced necrosis. Arch Pathol (1972) 1.09
Evolution of surveillance of measles, mumps, and rubella in England and Wales: providing the platform for evidence-based vaccination policy. Epidemiol Rev (2002) 1.09
Detection of human parvovirus B19-specific IgM and IgG antibodies using a recombinant viral VP1 antigen expressed in insect cells and estimation of time of infection by testing for antibody avidity. J Virol Methods (1993) 1.08
Healing process in the marginal zone of an experimental myocardial infarct. Findings in the surviving cardiac muscle cells. Am J Pathol (1971) 1.08
Laboratory infection with parvovirus B19. J Clin Pathol (1988) 1.07
Septoplasty complicated by staphylococcal spinal osteomyelitis. Arch Intern Med (1985) 1.05
Salivary diagnosis of rubella: a study of notified cases in the United Kingdom, 1991-4. Epidemiol Infect (1998) 1.05
The status and role of ErbB receptors in human cancer. Exp Mol Pathol (2008) 1.04
Serological study of rubella-like illnesses. J Med Virol (1987) 1.03
Primary liver cell cancer in Britain--a viral aetiology? Br Med J (1979) 1.02
Salivary antibody detection in epidemiological surveys: a pilot study after a mass vaccination campaign against rubella in São Paulo, Brazil. Trans R Soc Trop Med Hyg (1995) 1.02
Incorporation of a potent antileukemic agent, 5-aza-2'-deoxycytidine, into DNA of cells from leukemic mice. Cancer Res (1977) 1.01
Opportunity of detecting pre-hypertension: worldwide data on blood pressure overswinging. Biomed Pharmacother (2005) 1.01
Human parvovirus induced cytopenias: a report of five cases. Br J Haematol (1986) 1.00
Nakatani antigen and human parvovirus (B19) Lancet (1984) 1.00
Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy? Commun Dis Rep CDR Rev (1994) 0.99
Detection of parvovirus B19 DNA, antigen, and particles in the human fetus. J Med Virol (1987) 0.98
Wound repair in mice as influenced by age and antimacrophage serum. J Gerontol (1987) 0.97
Detection of IgG antibody to Epstein-Barr virus viral capsid antigen in saliva by antibody capture radioimmunoassay. J Virol Methods (1997) 0.97
The value of screening blood donors for antibody to hepatitis B core antigen. J Clin Pathol (1983) 0.97
Hepatitis B core antigen synthesised in Escherichia coli: its use for antibody screening in patients attending a clinic for sexually transmitted diseases. J Hyg (Lond) (1984) 0.96
HLA and acute arthritis following human parvovirus infection. Tissue Antigens (1986) 0.96
Parvovirus B19 as a cause of acquired chronic pure red cell aplasia. Br J Haematol (1994) 0.96
Effect of 5-aza-2'-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma (1968) 0.96
Sequence analysis of a parvovirus B19 isolate and baculovirus expression of the non-structural protein. Arch Virol (1996) 0.95
Human parvovirus (B19) and erythema infectiosum. J Pediatr (1985) 0.95
Prolonged parvovirus B19 infection with severe anaemia in a bone marrow transplant patient. Br J Haematol (1989) 0.95
Detection of measles specific IgG in oral fluid using an FITC/anti-FITC IgG capture enzyme linked immunosorbent assay (GACELISA). J Virol Methods (1999) 0.95
Prophylactic aspirin treatment: the merits of timing. International Womb-to-Tomb Chronome Study Group. JAMA (1991) 0.94
Dual infection with rubella and human parvovirus. Lancet (1985) 0.94
Transmission of human parvovirus B19 by coagulation factor concentrates. Vox Sang (1990) 0.94
Bone marrow necrosis in malignant diseases. A report on seven intravitally recognized cases. Neoplasma (1989) 0.93
Characteristics of mouse leukemic cells resistant to 5-azacytidine and 5-aza-2'-deoxycytidine. Cancer Res (1968) 0.93
Detection of rubella virus-specific immunoglobulin G in saliva by an amplification-based enzyme-linked immunosorbent assay using monoclonal antibody to fluorescein isothiocyanate. J Clin Microbiol (1999) 0.93
Evaluation of a synthetic-peptide enzyme-linked immunosorbent assay for immunoglobulin M to human parvovirus B19. J Clin Microbiol (1991) 0.93
Mode of action and effects of 5-azacytidine and of its derivatives in eukaryotic cells. Pharmacol Ther (1985) 0.92
Anemia and menstrual blood loss. Obstet Gynecol Surv (1980) 0.92
Human parvovirus B19 infected fetal liver as a source of antigen for a radioimmunoassay for B19 specific IgM in clinical samples. J Med Virol (1991) 0.92
Neuralgic amyotrophy due to parvovirus infection. J Neurol Neurosurg Psychiatry (1987) 0.92
Measles virus strains circulating in Ethiopia in 1998-1999: molecular characterisation using oral fluid samples and identification of a new genotype. J Med Virol (2001) 0.92
An enzyme-linked immunosorbent-assay test for hepatitis B surface antigen. J Clin Pathol (1977) 0.91
Absence of bacteremia during nasal septoplasty. Arch Otolaryngol Head Neck Surg (1991) 0.91
[Hereditary drusen of Bruch's membrane. II: Studies of semi-thin sections and electron microscopy results]. Klin Monbl Augenheilkd (1982) 0.90
Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res (2004) 0.90
Delta agent in Britain. Lancet (1983) 0.90
Erythema infectiosum in a village primary school: clinical and virological studies. J R Coll Gen Pract (1986) 0.90
In vitro propagation of parvovirus B19 in primary foetal liver culture. J Gen Virol (1991) 0.89
The prevalence of antibody to human parvovirus B19 in Rio de Janeiro, Brazil. Rev Inst Med Trop Sao Paulo (1991) 0.89
Influence of the bcg locus on natural resistance to primary infection with the facultative intracellular bacterium Francisella tularensis in mice. Infect Immun (2000) 0.89
Myocardial resistance. A study of its development against toxic doses of isoproterenol. Arch Pathol (1970) 0.89
Association of decreased uridine and deoxycytidine kinase with enhanced RNA and DNA polymerase in mouse leukemic cells resistant to 5-azacytidine and 5-aza-2'-deoxycytidine. Cancer Res (1970) 0.88
Phase I/II study of stage III and IV non-small cell lung cancer patients taking a specific dietary supplement. Nutr Cancer (1999) 0.88
Surgical prophylaxis of malignant melanoma. Ann Surg (1991) 0.88
Application to immunoglobulin M capture hemadherence assays of hemagglutination of monkey erythrocytes by native and recombinant human parvovirus B19 antigens. J Clin Microbiol (1994) 0.87
Changing the method of selection at Northwick Park. Br Med J (Clin Res Ed) (1982) 0.87
Prolongation of the lag period preceding the enhancement of thymidine and thymidylate kinase activity in regenerating rat liver by 5-azacytidine. Biochem Pharmacol (1972) 0.87
Antibody capture haemadherence tests for parvovirus B19-specific IgM and IgG. J Virol Methods (1993) 0.86
Meta-analyzed heart rate variability, exposure to geomagnetic storms, and the risk of ischemic heart disease. Scr Med (Brno) (1997) 0.86
Accelerated wound repair in old deer mice (Peromyscus maniculatus) and white-footed mice (Peromyscus leucopus). J Gerontol (1987) 0.86
Parvovirus B19 outbreak on an adult ward. Epidemiol Infect (1994) 0.86
Detection of B19 parvovirus in human fetal tissues by electron microscopy. J Med Virol (1991) 0.86
Resonance properties of the vocal folds: in vivo laryngoscopic investigation of the externally excited laryngeal vibrations. J Acoust Soc Am (2000) 0.86